Finding out you have precancerous cells in your cervix can sound alarming, but it’s not a cancer diagnosis. These abnormal cells are common, develop slowly, and in many cases can be monitored or treated before they ever become dangerous. Most people learn about them through a routine Pap smear or HPV test, since precancerous changes almost never cause symptoms you’d notice on your own.
What happens next depends on how abnormal the cells look under a microscope and how deep the changes go. Here’s what the process typically looks like, from diagnosis through treatment and follow-up.
Why You Won’t Feel Anything
Precancerous cervical cells don’t cause pain, bleeding, or discharge. They’re detected through screening, not symptoms. That’s exactly why regular Pap smears and HPV tests matter so much: they catch changes that are invisible to you. By the time cervical changes do cause symptoms like unusual bleeding or pelvic pain, they’ve usually progressed well beyond the precancerous stage.
How Precancerous Cells Are Graded
Not all precancerous cells are equally concerning. Pathologists grade them based on how much of the cervical lining is affected, using a system called CIN (cervical intraepithelial neoplasia).
- CIN 1 (low-grade): Abnormal cells are found only in the bottom third of the cervical lining. This is the mildest form and most likely to resolve on its own.
- CIN 2 (high-grade): Abnormal cells extend deeper, involving more of the tissue layers. This sits in a gray zone between “wait and watch” and “treat now.”
- CIN 3 (high-grade): Abnormal cells span the full thickness of the lining. This is the most advanced precancerous stage and the closest to becoming invasive cancer if left untreated.
The grade determines everything that follows: how closely you’re monitored, whether treatment is recommended, and how urgently.
What Happens During Diagnosis
If your Pap smear or HPV test comes back abnormal, the next step is usually a colposcopy. You lie on an exam table with your feet in stirrups, and a speculum is inserted just like during a Pap. Your provider then uses a colposcope, which is essentially a magnifying instrument with a bright light, to get a close-up view of your cervix. It doesn’t enter your body.
If anything looks abnormal through the colposcope, your provider takes a small tissue sample (biopsy) right then. This is typically a punch biopsy, where a tiny circular piece of tissue is removed in one quick motion, or a scraping of the cervical canal lining. Most people describe it as a sharp pinch or cramp that lasts a few seconds. Some providers use a numbing spray or local anesthetic. The tissue goes to a lab, and results usually come back within one to two weeks.
Many Cases Resolve Without Treatment
One of the most reassuring facts about precancerous cervical cells is that your immune system often clears them on its own, especially in younger women. CIN 1 is the stage most likely to disappear without intervention, which is why the standard approach is simply monitoring with repeat testing rather than jumping to treatment.
Even CIN 2 has a strong track record of resolving. In a study of women under 25, 76% of CIN 2 cases regressed completely to normal tissue during a watch-and-wait period, with another 12% improving partially to CIN 1. Only 12% persisted without changing. CIN 3 is less likely to clear on its own. In the same study, only about 14% of CIN 3 cases regressed completely to normal, and roughly 25% showed any improvement within three years.
Because of these patterns, doctors often recommend active surveillance for CIN 1 and sometimes for CIN 2, particularly in younger patients who may want to preserve fertility. CIN 3 almost always warrants treatment.
How Slowly This Progresses
Precancerous cells don’t become cancer overnight. The progression from early abnormalities to more advanced changes typically unfolds over years, not months. Research tracking women over time found that the average progression from low-grade abnormalities to high-grade changes took roughly six to seven years, even in women infected with high-risk HPV strains. Without those strains, it took even longer.
The full timeline from initial HPV infection to invasive cervical cancer is generally estimated at 10 to 20 years for most people. This slow pace is precisely what makes screening so effective. Regular testing gives you and your provider a wide window to catch and address changes before they become serious.
Treatment Options for Higher-Grade Changes
When precancerous cells need to be removed, the two most common procedures are LEEP and cold knife conization. Both remove the abnormal tissue from the cervix, but they differ in approach.
LEEP (loop electrosurgical excision procedure) uses a thin wire loop carrying an electrical current to shave off the affected tissue. It’s typically done in an office or outpatient clinic under local anesthesia. The procedure takes about 10 to 20 minutes, and most people go home the same day with mild cramping.
Cold knife conization is a more traditional surgical approach, usually performed in a hospital under general or regional anesthesia. It removes a cone-shaped piece of cervical tissue and tends to take more tissue than LEEP. It’s generally reserved for cases where a larger or more precise sample is needed.
Both procedures are highly effective. Recovery typically involves a few weeks of avoiding tampons, intercourse, and heavy lifting. Light spotting or discharge is normal during healing.
What Treatment Means for Future Pregnancies
If you’re planning to have children, this is likely one of your biggest concerns. The short answer: most people go on to have healthy, full-term pregnancies after treatment. But the amount of tissue removed matters.
Women who’ve had a LEEP are at roughly twice the general risk of preterm birth. However, more recent research has refined this picture considerably. Excisions that remove less than 10 mm of tissue appear to have minimal, if any, effect on preterm birth risk. The risk climbs with larger excisions, particularly those removing more than 15 mm of tissue. At 20 mm or more, roughly one in six pregnancies ends in preterm delivery.
If you’ve had a large excision, your provider will likely monitor your cervical length by ultrasound between 16 and 24 weeks of pregnancy. A shorter cervix at that point can flag higher risk for early delivery, allowing your care team to take preventive steps. For most women with smaller excisions, no special pregnancy monitoring is needed.
Follow-Up After Treatment
Treatment isn’t the end of the process. Recurrence rates for high-grade precancerous changes run between 10% and 14% even after successful removal, so ongoing monitoring is essential.
Current guidelines recommend HPV testing or a combination of HPV testing and Pap smears at one year after treatment. If those results are normal, you move to testing every three years. This more frequent surveillance schedule continues for at least 25 years after treatment of high-grade changes, regardless of your age. That’s a longer follow-up window than many people expect, but it reflects the fact that the underlying HPV infection can sometimes reactivate.
HPV Vaccination Still Helps
You might assume the HPV vaccine is pointless if you’ve already been diagnosed with precancerous cells. It’s not. Getting vaccinated around the time of treatment, if you haven’t been vaccinated before, reduces the risk of recurrence by about 65%, according to a meta-analysis of over 21,000 patients. The vaccine protects against HPV strains you haven’t yet been exposed to, which can cause new infections in tissue that’s already been treated.
ACOG recommends vaccination for anyone up to age 26 and suggests considering it for unvaccinated people ages 27 to 45 who are undergoing treatment for high-grade precancerous changes. The benefit is real and measurable: fewer recurrences, fewer repeat procedures, and fewer follow-up tests over time.